2026-02-24
Alcohol, Aging, and Long-Term Health: What the Evidence Shows
Alcohol consumption interacts with aging biology in complex ways. This article covers the liver, brain, cardiovascular, and cancer evidence, plus what nutritional strategies can mitigate harm.
2026-02-24
Grip Strength as a Longevity Biomarker: Evidence and Interventions
Grip strength is one of the most powerful and accessible biomarkers of biological aging, predicting cardiovascular events, hospitalization, and all-cause mortality more reliably than many clinical tests. This article covers the mechanisms, evidence, and interventions.
2026-02-23
Blood Sugar and Insulin Resistance: Supplement Protocol, Monitoring, and Evidence Summary
Insulin resistance precedes type 2 diabetes by years and independently drives cardiovascular risk, cognitive decline, and accelerated aging. Berberine, magnesium, alpha-lipoic acid, and chromium have the best evidence among supplements. This protocol integrates the strongest interventions with clear monitoring markers.
2026-02-22
Anemia and Iron Deficiency in Aging: Diagnosis, Causes, and Supplementation Evidence
Anemia affects 10–20% of adults over 65 and is independently associated with frailty, cognitive decline, and mortality. Iron deficiency is the most common cause but is often missed in older adults. Supplementation restores function when deficiency is confirmed — but iron excess is harmful and routine supplementation without deficiency is not indicated.
2026-02-18
Partial Epigenetic Reprogramming for Vision Loss: Life Biosciences ER-100 Trial
Life Biosciences received FDA clearance to begin the first human trial of partial epigenetic reprogramming using OSK Yamanaka factors delivered via AAV for glaucoma and NAION. Trial is in early stages; no human efficacy data exists yet.